Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update

References

• Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24(1):677–736. doi: 10.1146/annurev.neuro.24.1.677
   PubMed Web of Science ®Google Scholar
• Kaplan DR, Stephens RM. Neurotrophin signal transduction by the Trk receptor. J Neurobiol. 1994;25(11):1404–1417. doi: 10.1002/neu.480251108
   PubMedGoogle Scholar
• Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc B. 2006;361(1473):1545–1564. doi: 10.1098/rstb.2006.1894
   PubMed Web of Science ®Google Scholar
• Valnegri P, Puram SV, Bonni A. Regulation of dendrite morphogenesis by extrinsic cues. Trends Neurosci. 2015;38(7):439–447. doi: 10.1016/j.tins.2015.05.003
   PubMed Web of Science ®Google Scholar
• Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Revi Biochem. 2003;72(1):609–642. doi: 10.1146/annurev.biochem.72.121801.161629
   PubMed Web of Science ®Google Scholar
• Ohira K, Hayashi M. A new aspect of the TrkB signaling pathway in neural plasticity. Curr Neuropharmacol. 2009;7(4):276–285. doi: 10.2174/157015909790031210
   PubMed Web of Science ®Google Scholar
• Thoenen H. Neurotrophins and neuronal plasticity. Science. 1995;270(5236):593–598. doi: 10.1126/science.270.5236.593
   PubMed Web of Science ®Google Scholar
• Castrén E, Antila H. Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry. 2017;22(8):1085–1095. doi: 10.1038/mp.2017.61
   PubMed Web of Science ®Google Scholar
• Smeyne RJ, Klein R, Schnapp A, et al. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature. 1994;368(6468):246–249. doi: 10.1038/368246a0
   PubMed Web of Science ®Google Scholar
• Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol. 1994;25(11):1386–1403. doi: 10.1002/neu.480251107
   PubMedGoogle Scholar
• Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34. doi: 10.1158/2159-8290.CD-14-0765
   PubMed Web of Science ®Google Scholar
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–747. doi: 10.1038/s41571-018-0113-0
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Bencardino K, et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30(Suppl_8):viii5–viii15. doi: 10.1093/annonc/mdz383
   PubMedGoogle Scholar
• Hsiao SJ, Zehir A, Sireci AN, et al. Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy. J Mol Diagn. 2019;21(4):553–571. doi: 10.1016/j.jmoldx.2019.03.008
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Xiu J, Swensen J, et al. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147–153. doi: 10.1038/s41379-018-0118-3
   PubMed Web of Science ®Google Scholar
• Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417–1427. doi: 10.1093/annonc/mdz204
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023. doi: 10.1136/esmoopen-2015-000023
   PubMed Web of Science ®Google Scholar
• Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367–376. doi: 10.1016/S1535-6108(02)00180-0
   PubMed Web of Science ®Google Scholar
• Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5(1):69. doi: 10.1038/s41698-021-00206-y
   PubMed Web of Science ®Google Scholar
• Lagadec C, Meignan S, Adriaenssens E, et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene. 2009;28(18):1960–1970. doi: 10.1038/onc.2009.61
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15(10):3244–3250. doi: 10.1158/1078-0432.CCR-08-1815
   PubMed Web of Science ®Google Scholar
• Kyker-Snowman K, Hughes RM, Yankaskas CL, et al. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Res Treat. 2020;179(3):631–642. doi: 10.1007/s10549-019-05506-3
   PubMed Web of Science ®Google Scholar
• Griffin N, Marsland M, Roselli S, et al. The receptor tyrosine kinase TrkA is increased and targetable in HER2-positive breast cancer. Biomolecules. 2020;10(9):1329. doi: 10.3390/biom10091329
   PubMed Web of Science ®Google Scholar
• Regua AT, Doheny D, Arrigo A, et al. Trk receptor tyrosine kinases in metastasis and cancer therapy. Discov Med. 2019;28(154):195–203.
   PubMed Web of Science ®Google Scholar
• Descamps S, Pawlowski V, Révillion F, et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res. 2001;61(11):4337–4340.
   PubMed Web of Science ®Google Scholar
• Ginsberg SD, Che S, Wuu J, et al. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J Neurochem. 2006;97(2):475–487. doi: 10.1111/j.1471-4159.2006.03764.x
   PubMed Web of Science ®Google Scholar
• Baydyuk M, Nguyen MT, Xu B. Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration. Exp Neurol. 2011;228(1):118–125. doi: 10.1016/j.expneurol.2010.12.018
   PubMed Web of Science ®Google Scholar
• Gupta VK, You Y, Gupta VB, et al. TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int J Mol Sci. 2013;14(5):10122–10142. doi: 10.3390/ijms140510122
   PubMed Web of Science ®Google Scholar
• Tejeda GS, Díaz-Guerra M. Integral characterization of defective BDNF/TrkB signalling in neurological and psychiatric disorders leads the way to new therapies. Int J Mol Sci. 2017;18(2):268. doi: 10.3390/ijms18020268
   PubMed Web of Science ®Google Scholar
• Espinera AR, Ogle ME, Gu X, et al. Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Neuroscience. 2013;247:1–11. doi: 10.1016/j.neuroscience.2013.04.011
   PubMed Web of Science ®Google Scholar
• Middlemas DS, Lindberg RA, Hunter T. trkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol. 1991;11(1):143–153. doi: 10.1128/mcb.11.1.143-153.1991
   PubMed Web of Science ®Google Scholar
• Fenner ME, Achim CL, Fenner BM. Expression of full-length and truncated trkB in human striatum and substantia nigra neurons: implications for Parkinson’s disease. J Mol Histol. 2014;45(3):349–361. doi: 10.1007/s10735-013-9562-z
   PubMed Web of Science ®Google Scholar
• Wong J, Higgins M, Halliday G, et al. Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer’s disease. Neuroscience. 2012;210:363–374. doi: 10.1016/j.neuroscience.2012.02.037
   PubMed Web of Science ®Google Scholar
• Eide FF, Vining ER, Eide BL, et al. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci. 1996;16(10):3123–3129. doi: 10.1523/JNEUROSCI.16-10-03123.1996
   PubMed Web of Science ®Google Scholar
• Haapasalo A, Koponen E, Hoppe E, et al. Truncated trkB.T1 is dominant negative inhibitor of trkB.TK±mediated cell survival. Biochem Biophys Res Commun. 2001;280(5):1352–1358. doi: 10.1006/bbrc.2001.4296
   PubMed Web of Science ®Google Scholar
• Wu J, Renn CL, Faden AI, et al. TrkB.T1 contributes to neuropathic pain after spinal cord injury through regulation of cell cycle pathways. J Neurosci. 2013;33(30):12447–12463. doi: 10.1523/JNEUROSCI.0846-13.2013
   PubMed Web of Science ®Google Scholar
• Di Giovanni S, Movsesyan V, Ahmed F, et al. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci USA. 2005;102(23):8333–8338. doi: 10.1073/pnas.0500989102
   PubMed Web of Science ®Google Scholar
• Wei X, Wang L, Hua J, et al. Inhibiting BDNF/TrkB.T1 receptor improves resiniferatoxin-induced postherpetic neuralgia through decreasing ASIC3 signaling in dorsal root ganglia. J Neuroinflammation. 2021;18(1):96. doi: 10.1186/s12974-021-02148-5
   PubMed Web of Science ®Google Scholar
• Cao T, Matyas JJ, Renn CL, et al. Function and mechanisms of truncated BDNF receptor TrkB.T1 in neuropathic pain. Cells. 2020;9(5):1194. doi: 10.3390/cells9051194
   PubMed Web of Science ®Google Scholar
• Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27(2):85–91. doi: 10.1016/j.tips.2005.12.001
   PubMed Web of Science ®Google Scholar
• Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nature Genet. 1996;13(4):485–488. doi: 10.1038/ng0896-485
   PubMed Web of Science ®Google Scholar
• Miranda C, Di Virgilio M, Selleri S, et al. Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type 1/nerve growth factor receptor mutations. J Biol Chem. 2002;277(8):6455–6462. doi: 10.1074/jbc.M110016200
   PubMed Web of Science ®Google Scholar
• Slater D, Kunnathil S, McBride J, et al. Pharmacology of nonsteroidal antiinflammatory drugs and opioids. Semin Intervent Radiol. 2010;27(4):400–411. doi: 10.1055/s-0030-1267855
   PubMedGoogle Scholar
• Patel MK, Kaye AD, Urman RD. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol. 2018;34(1):111–116. doi: 10.4103/joacp.JOACP_389_15
   PubMed Web of Science ®Google Scholar
• Zhao D, Luo MH, Pan JK, et al. Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2022;14:1759720x211067639. doi: 10.1177/1759720X211067639
   Web of Science ®Google Scholar
• Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017;35 Suppl 107(5):85–87.
   PubMed Web of Science ®Google Scholar
• Paula D, Alan JK, Joseph SG, et al. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial. Ann Rheumatic Dis. 2021;80(4):509. doi: 10.1136/annrheumdis-2020-217259
   PubMed Web of Science ®Google Scholar
• Norman BH, McDermott JS. Targeting the nerve growth factor (NGF) pathway in drug discovery. Potential applications to new therapies for chronic pain. J Med Chem. 2017;60(1):66–88. doi: 10.1021/acs.jmedchem.6b00964
   PubMed Web of Science ®Google Scholar
• Bagal SK, Andrews M, Bechle BM, et al. Discovery of potent, selective, and peripherally restricted pan-trk kinase inhibitors for the treatment of pain. J Med Chem. 2018;61(15):6779–6800. doi: 10.1021/acs.jmedchem.8b00633
   PubMed Web of Science ®Google Scholar
• Bertrand T, Kothe M, Liu J, et al. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol. 2012;423(3):439–453. doi: 10.1016/j.jmb.2012.08.002
   PubMed Web of Science ®Google Scholar
• Treiber Daniel K, Shah Neil P. Ins and outs of kinase DFG motifs. Chem Biol. 2013;20(6):745–746. doi: 10.1016/j.chembiol.2013.06.001
   PubMedGoogle Scholar
• Wu T, Zhang C, Lv R, et al. Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors. Eur J Med Chem. 2021;223:113627. doi: 10.1016/j.ejmech.2021.113627
   PubMed Web of Science ®Google Scholar
• Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lan Oncol. 2020;21(4):531–540. doi: 10.1016/S1470-2045(19)30856-3
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi: 10.1056/NEJMoa1714448
   PubMed Web of Science ®Google Scholar
• Cocco E, Lee JE, Kannan S, et al. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. Cancer Discov. 2021;11(1):126–141. doi: 10.1158/2159-8290.CD-20-0571
   PubMed Web of Science ®Google Scholar
• Xiang S, Wang J, Huang H, et al. Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy. Eur J Med Chem. 2023;245:114899. doi: 10.1016/j.ejmech.2022.114899
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wu H, Wang L, et al. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol. 2014;9(6):1230–1241. doi: 10.1021/cb500129t
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou Y, Tang X, et al. JND4135, a new type II TRK inhibitor, overcomes TRK xDFG and other mutation resistance in vitro and in vivo. Molecules (Basel, Switzerland). 2022;27(19). doi: 10.3390/molecules27196500
   Web of Science ®Google Scholar
• Albaugh P, Fan Y, Mi Y, et al. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett. 2012;3(2):140–145. doi: 10.1021/ml200261d
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308. doi: 10.1158/1535-7163.MCT-11-0264
   PubMed Web of Science ®Google Scholar
• Patwardhan PP, Ivy KS, Musi E, et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget. 2016;7(4):4093–4109. doi: 10.18632/oncotarget.6547
   PubMedGoogle Scholar
• Yan W, Lakkaniga NR, Carlomagno F, et al. Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application. J Med Chem. 2019;62(4):1731–1760. doi: 10.1021/acs.jmedchem.8b01092
   PubMed Web of Science ®Google Scholar
• Su H-P, Rickert K, Burlein C, et al. Structural characterization of nonactive site, TrkA-selective kinase inhibitors. Proc Nat Acad Sci. 2017;114(3):E297–E306. doi: 10.1073/pnas.1611577114
   PubMed Web of Science ®Google Scholar
• Allen S, Andrews SW, Blake JF, et al. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors. WO2012158413. 2012.
   Google Scholar
• Martinez R, Defnet A, Shapiro P. Avoiding or co-opting ATP inhibition: overview of type III, IV, V, and VI kinase inhibitors. In: Shapiro P, editor. Next generation kinase inhibitors: moving beyond the ATP binding/catalytic sites. Cham: Springer International Publishing; 2020. p. 29–59.
   Google Scholar
• McCarthy C, Walker E. Tropomyosin receptor kinase inhibitors: a patent update 2009 – 2013. Expert Opin Ther Patents. 2014;24(7):731–744. doi: 10.1517/13543776.2014.910195
   PubMed Web of Science ®Google Scholar
• Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – part I. Expert Opin Ther Patents. 2017;27(6):733–751. doi: 10.1080/13543776.2017.1297796
   PubMed Web of Science ®Google Scholar
• Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – part II. Expert Opin Ther Patents. 2017;27(7):831–849. doi: 10.1080/13543776.2017.1297797
   PubMed Web of Science ®Google Scholar
• Bailey JJ, Jaworski C, Tung D, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019. Expert Opin Ther Patents. 2020;30(5):325–339. doi: 10.1080/13543776.2020.1737011
   PubMed Web of Science ®Google Scholar
• Jaworski C, Petar I, Wängler C, et al. Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update. Expert Opin Ther Pat. 2023 Jul;33(7–8):503–521. doi: 10.1080/13543776.2023.2262136
   PubMed Web of Science ®Google Scholar
• Xiaoyun L, Xun H, Shuang X, et al. Imidazopyridazine derivative and application thereof. CN114989176. 2022.
   Google Scholar
• Choi HS, Rucker PV, Wang Z, et al. (R)-2-phenylpyrrolidine substituted imidazopyridazines: a new class of potent and selective pan-TRK inhibitors. ACS Med Chem Lett. 2015;6(5):562–567. doi: 10.1021/acsmedchemlett.5b00050
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412. doi: 10.1016/j.ccr.2009.09.028
   PubMed Web of Science ®Google Scholar
• Lu X, Zhang Z, Ding K, et al. Alkynylphenylbenzamide compound and use thereof. WO2022217821. 2022.
   Google Scholar
• Sintim HO, Larocque EA, Hernandez DE, et al. 2,3-Disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors. WO2021262915. 2021.
   Google Scholar
• Wang M, Naganna N, Sintim HO. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma. Bioorg Chem. 2019;90:103052. doi: 10.1016/j.bioorg.2019.103052
   PubMed Web of Science ®Google Scholar
• Larocque E, Chu EFY, Naganna N, et al. Nicotinamide–ponatinib analogues as potent anti-CML and anti-AML compounds. ACS Omega. 2020;5(6):2690–2698. doi: 10.1021/acsomega.9b03223
   PubMed Web of Science ®Google Scholar
• Ardini E, Bosotti R, Borgia AL, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014;8(8):1495–1507. doi: 10.1016/j.molonc.2014.06.001
   PubMed Web of Science ®Google Scholar
• Cheng H, Wen X, Liu Z, et al. Pyridone compound, preparation method therefor, and application thereof. WO2022017524. 2022.
   Google Scholar
• Esteban I, Levanti B, Garcia-Suarez O, et al. A neuronal subpopulation in the mammalian enteric nervous system expresses TrkA and TrkC neurotrophin receptor-like proteins. Anat Rec. 1998;251(3):360–370. doi: 10.1002/(SICI)1097-0185(199807)251:3<360:AID-AR12>3.0.CO;2-M
   PubMedGoogle Scholar
• Eidam HS, Demartino MP, Gong Z, et al. Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors. WO2014141187. 2014.
   Google Scholar
• Liu Q, Liu J, Wang B, et al. New use of indazole compound. WO2021174581. 2021.
   Google Scholar
• Liu X, Wang B, Chen C, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur J Med Chem. 2018;160:61–81. doi: 10.1016/j.ejmech.2018.10.007
   PubMed Web of Science ®Google Scholar
• Wang B, Zhang W, Liu X, et al. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. Eur J Med Chem. 2020;207:112744. doi: 10.1016/j.ejmech.2020.112744
   PubMed Web of Science ®Google Scholar
• Zhong B, Zhang TT, Cao Y, et al. Trk inhibitor as anti-cancer drug. WO2020048455. 2020.
   Google Scholar
• Konicek BW, Capen AR, Credille KM, et al. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. Oncotarget. 2018;9(17):13796–13806. doi: 10.18632/oncotarget.24488
   PubMedGoogle Scholar
• Zhong B, Zhang T, Dong C, et al. Abstract 4027: TSN084, a multi-kinase inhibitor, overcomes acquired drug-resistant mutations of cMet, Trks, and Flt3, and displays broad activities against kinase oncotargets Axl, DDRs, and CDK8/19. Cancer Res. 2023;83(7_Supplement):4027–27. doi: 10.1158/1538-7445.AM2023-4027
   Web of Science ®Google Scholar
• Furuya N, Momose T, Katsuno K, et al. The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity. Bioorganic Med Chem Lett. 2017;27(5):1233–1236. doi: 10.1016/j.bmcl.2017.01.056
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu W, Li Z, et al. Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases. WO2020011227. 2020.
   Google Scholar
• Hong F, Chen Z, Wang L, et al. Crystal form of pyrrolidinyl urea derivative and application thereof. WO2021139794. 2021.
   Google Scholar
• Zhang Y, Wu W, Teng M, et al. Pyrrolidinyl urea derivatives and application thereof. WO2020083377. 2020.
   Google Scholar
• Liu J, Wang J, Han X, et al. Tropomyosin receptor kinase (Trk) degradation compounds and methods of use. WO2022218289. 2022.
   Google Scholar
• Liu D, Flory J, Lin A, et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol. 2020;31(9):1207–1215. doi: 10.1016/j.annonc.2020.05.006
   PubMed Web of Science ®Google Scholar
• Wang G, Wu Y, Wu C, et al. Rational design and crystallographic analysis of novel isoform-selective TRKA inhibitors for cancer therapy. Acta Pharm Sin B. 2023;13(1):440–443. doi: 10.1016/j.apsb.2022.10.012
   PubMed Web of Science ®Google Scholar
• Wang Z, Ren J, Jia K, et al. Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor. Eur J Med Chem. 2022;241:114601. doi: 10.1016/j.ejmech.2022.114601
   PubMed Web of Science ®Google Scholar
• Guo J, Xiang S, Wang J, et al. Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies. Eur J Med Chem. 2022;228:114022. doi: 10.1016/j.ejmech.2021.114022
   PubMed Web of Science ®Google Scholar
• Subramanian G, Duclos B, Johnson PD, et al. In pursuit of an allosteric human tropomyosin kinase a (hTrkA) inhibitor for chronic pain. ACS Med Chem Lett. 2021;12(11):1847–1852. doi: 10.1021/acsmedchemlett.1c00483
   PubMed Web of Science ®Google Scholar
• Bagal SK, Omoto K, Blakemore DC, et al. Discovery of allosteric, potent, subtype selective, and peripherally restricted TrkA kinase inhibitors. J Med Chem. 2019;62(1):247–265. doi: 10.1021/acs.jmedchem.8b00280
   PubMed Web of Science ®Google Scholar
• Tang S, Xue Y, Dengqi X, et al. Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem. 2023;245:114901. doi: 10.1016/j.ejmech.2022.114901
   PubMed Web of Science ®Google Scholar
• Nordvall G, Dahlström M, Parrado-Fernandez C, et al. Negative allosteric modulators of TrkA for the treatment of pain. In: International Association for the Study of Pain (IASP), 2021 Jun 27 - Jul 02; Amsterdam; 2021.
   Google Scholar
• Cui J, Xiao Z, Zhang LL. Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer: study protocol for a prospective, multicenter, open-label. Medicine (Baltimore). 2021;100(21):e25992. doi: 10.1097/MD.0000000000025992
   PubMed Web of Science ®Google Scholar